Lifeboat Foundation

Building upon the foundational paradigms outlined in The Syntellect Hypothesis: Five Paradigms of the Mind’s Evolution (2020), my latest work titled The Cybernetic Theory of Mind (2022), a Kindle eBook series published last year, serves as an extension and refinement, operating at the intersection of information physics, quantum cosmology, and simulation metaphysics. The objective is not merely to inform but to elucidate through an “explanatory” theory of everything, providing an integrative framework for a deeper understanding of reality.

#CyberneticTheory #InformationPhysics #QuantumCosmology #SimulationMetaphysics #cybernetics #QuantumGravity #SyntellectHypothesis #CyberneticTheoryofMind #TheoryofEverything #consciousness #TechnologicalSingularity #DigitalPhysics #QuantumMechanics #PhilosophyofMind #posthumanism #UniversalMind #CyberneticImmortality

The Cybernetic Theory of Mind is an explanatory TOE at the intersection of information physics, quantum cosmology and simulation metaphysics.

Continue reading “Cybernetic Theory: Information Physics, Quantum Cosmology, Simulation Metaphysics” »

“For those who have lost their ability to communicate due to a variety of neurological conditions, there’s a lot of hope to preserve or regain their ability to communicate with family and friends.”

The term “brain-computer interface” (BCI) refers to a technology that creates a direct line of communication between the human brain and an outside object or computer system, opening up a wide range of possibilities for things like device control and neurological study.

Oonal/iStock.

Continue reading “ALS patients control home devices with their minds using BCI” »

Scientists have made remarkable progress in understanding the underlying changes that make cancer grow and have applied this knowledge to develop and guide targeted treatment approaches to vastly improve outcomes for people with many cancer types. And yet treatment progress for people with brain tumors known as gliomas—including the most aggressive glioblastomas—has remained slow. One reason is that doctors lack tests that reliably predict which among many therapeutic options will work best for a given tumor.

Now an NIH-funded team has developed a miniature device with the potential to change this for the approximately 25,000 people diagnosed with brain cancers in the U.S. each year [1]. When implanted into cancerous brain tissue during surgery, the rice-sized drug-releasing device can simultaneously conduct experiments to measure a tumor’s response to more than a dozen drugs or drug combinations. What’s more, a small clinical trial reported in Science Translational Medicine offers the first evidence in people with gliomas that these devices can safely offer unprecedented insight into tumor-specific drug responses [2].

These latest findings come from a Brigham and Women’s Hospital, Boston, team led by Pierpaolo Peruzzi and Oliver Jonas. They recognized that drug-screening studies conducted in cells or tissue samples in the lab too often failed to match what happens in people with gliomas undergoing cancer treatment. Wide variation within individual brain tumors also makes it hard to predict a tumor’s likely response to various treatment options.

For those with stubbornly resistant forms of severe depression, ketamine was looking more and more like a solution. Years of research has hinted at the dissociative anesthetic’s treatment potential where other medications failed, promising the benefits of electroshock therapy with far fewer risks.

For all of the excitement, separating the hope from the hype has been challenged by the drug’s strong psychoactive effects. How can you conduct a blind test for a drug that so overtly detaches the mind from the body?

By taking advantage of the unconscious state of patients under general anesthesia, researchers from Stanford University School of Medicine in the US put ketamine to the ultimate, gold standard test.

Having more pixels could advance everything from biomedical imaging to astronomical observations.

Researchers at the National Institute of Standards and Technology (NIST) and their colleagues have built a superconducting camera containing 400,000 pixels — 400 times more than any other device of its type.

Superconducting cameras allow scientists to capture very weak light signals, whether from distant objects in space or parts of the human brain. Having more pixels could open up many new applications in science and biomedical research.

A meta-analysis showed improvement of neuropsychiatric symptoms with acetylcholinesterase inhibitors in Alzheimer disease and Parkinson disease, although effect sizes were small.

Neuropsychiatric symptoms are challenging to treat in patients with neurodegenerative conditions. In this meta-analysis, researchers investigated the effect of cholinesterase inhibitors (ChEI) on neuropsychiatric symptoms in those with Alzheimer disease (AD) or Parkinson disease (PD). Studies in the analysis included placebo-controlled, randomized clinical trials that included at least one ChEI — i.e., donepezil, rivastigmine, or galantamine — and applied at least one validated neuropsychiatric measure, with the Neuropsychiatric Inventory (NPI) being the most used measure studied. The primary outcomes were hallucinations and delusions. Secondary outcomes included all other neuropsychiatric outcomes.

Original participant data for 6,649 individuals with AD or PD from 17 trials were available for analysis out of 34 eligible trials. In patients with AD, ChEI use was associated with significantly fewer delusions (effect size, −0.08) and hallucinations (−0.09) compared with placebo. In the PD subgroup, ChEIs also were associated with significantly fewer delusions (−0.14) and hallucinations (−0.08). These effects did not differ among ChEI types. ChEIs were associated with lower appetite scores in the AD group and with significantly improved total neuropsychiatric scores in the PD group (−0.18). Increases in baseline neuropsychiatric scores were associated with greater effect size favoring ChEIs in those with PD. Lower baseline cognitive score was associated with increased effect size favoring ChEIs in both AD and PD.

Based on this meta-analysis, ChEIs could be considered in appropriate patients, since ChEIs may reduce hallucinations and delusions in people with AD or PD. Greater effects may be possible if neuropsychiatric symptoms or lower cognitive scores are present at the time of initiation. ChEIs decreased appetite scores in AD, which should be considered in those who are underweight. Whether ChEIs also improve neuropsychiatric symptoms in dementia with Lewy bodies requires further study, since data were insufficient to assess that population in this analysis.

Continue reading “Cholinesterase Inhibitors and Psychiatric Symptoms in Alzheimer Disease and Parkinson Disease” »

Neurologists at the biggest Alzheimer’s research meeting in the US experienced something this week they hadn’t in years: optimism.

UFMG-V4N2 proved effective in producing antibodies and making them block the passage of cocaine into the brain, which means that the vaccinated animals have a reduced perception of the drug’s effect: a very important advantage in a treatment.

This blockage occurs in the following way: we have a “protective shield” called the blood-brain barrier, which prevents toxic elements, viruses or bacteria from entering the brain, but because the cocaine molecule is very small, it manages to pass through this barrier.

The vaccine stimulates the production of antibodies, which bind to the drug molecules, increasing their weight and size and thus preventing them from getting past the protective shield. The cocaine is retained in the blood, but as it is bound to the antibody, it doesn’t act on the heart or arteries either, which means the risk of overdoses is reduced.

Continue reading “Crack vaccine research on rats could help babies of mothers who use cocaine—and reduce addiction” »

Cocaine use continues to be a public health problem, yet despite concerted efforts, no drugs have been approved to resolve cocaine addiction. Research suggests that the attention-deficit/hyperactivity disorder drug methylphenidate (MPH; Ritalin) could serve as a cocaine-replacement therapy, but clinical results have been mixed. Although several labs have produced MPH derivatives for testing, parts of the molecule remained chemically inaccessible. Now, researchers reporting in ACS Central Science have cleared that hurdle.

According to the Centers for Disease Control and Prevention, more than 5 million Americans reported actively using cocaine in 2020, and almost 25,000 Americans died of a cocaine-related overdose in 2021. Although small-molecule drugs have proven effective in treating other drug addictions—for example, methadone as a therapy for heroin abuse—no such medication exists for cocaine abuse.

MPH has been considered a potential treatment because it behaves similarly to the illicit drug, increasing dopamine levels in the brain by blocking dopamine reuptake. Additionally, clinical studies have shown that MPH has a lower risk of abuse than cocaine.